Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186741 | 0.86 | POLB (0.47) | TSHRSMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL28343287 | 0.86 | GAA (0.49) | TSHRSMN1; SMN2POLBTP53THRB | |
| SCHEMBL9069782 | 0.83 | POLB (0.48) | TSHRSMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL5508940 | 0.83 | POLB (0.60) | TSHRSMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL7559149 | 0.82 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL2562392 | 0.81 | POLB (0.51) | TSHRSMN1; SMN2POLBTHRBTRPM8 | |
| SCHEMBL4036418 | 0.81 | GAA (0.54) | SMN1; SMN2POLBTP53TRPM8GAA | |
| SCHEMBL19027670 | 0.81 | TSHR (0.48) | TSHRSMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL30528370 | 0.80 | POLB (0.50) | TSHRSMN1; SMN2POLBTHRBTRPM8 | |
| SCHEMBL666126 | 0.80 | OPRM1 (0.53) | TSHRSMN1; SMN2POLBTHRBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | TSHR 3637/4885SMN1; SMN2 1121/4885ALOX15 4813/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | TSHR 3637/4885SMN1; SMN2 1121/4885ALOX15 4813/4885 |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | IDH1, IDH3B, IDH3A | TSHR 3637/4885SMN1; SMN2 1121/4885ALOX15 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.